Health Care · Pharmaceutical Preparations

ANNX Annexon, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 152811598 filings
Russell 2000

ANNX at a glance

Annexon, Inc. (ANNX, SEC CIK 1528115) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Annexon, Inc. (ANNX) shares worth $247.0 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Carson William H. on November 19, 2026 of 34,000 shares at $3.58 per share.
  • In the last 90 days, ANNX insiders reported 2 open-market purchases ($222K) and 0 open-market sales ($0) on Form 4, a net purchase of $222K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
2 buys · 0 sells
Net +$222K
13F holders
29 funds
$247.0M · +1 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New financing risk: July 2026 Loan Agreement added $50.0 million debt, with floating interest of at least 7.60% and substantially all assets pledged
  • Most material clinical update: ARCHER II expanded in August 2026 with Month 24 dual primary endpoint and open-label extension, increasing duration, complexity and funding needs
  • Regulatory risk: FDA indicated tanruprubart’s foreign-data generalizability package may require additional GBS patient data before BLA approval
  • Competitive risk: Two approved GA products may limit vonaprument adoption if it reaches commercialization
  • Liquidity risk: $213.4 million in cash and short-term investments expected to fund operations into 2028, but expanded Phase 3 work may require earlier financing

Management Discussion & Analysis

  • No product revenue; quarterly net loss $51.2M vs $54.9M YoY, down 7%
  • R&D expenses $41.4M vs $49.7M YoY, down 17%, driven by lower contract manufacturing
  • G&A expenses $10.9M vs $7.3M YoY, up 49%, worst cost trend versus R&D
  • Cash and investments $213.4M; operating cash use $143.5M through nine months vs $140.4M YoY
  • $50.0M term loan funded; cash runway into 2028, with substantial additional financing required

AI summary of the ANNX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter 2026 financial results announced for period ended September 30, 2026
  • Business updates and anticipated milestones included in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue-free biotech reported net loss $51.2M, or $0.25 per share, versus $54.9M, or $0.37, prior year
  • Cash, equivalents and short-term investments $213.4M at September 30, supporting anticipated operations into 2028
Filed Aug 12, 2026Full analysis →

Item 8.01: Other Events

  • Annexon expanded vonaprument’s Phase 3 geographic atrophy program with a Month 24 dual primary endpoint
  • Month 24 endpoint complements the existing Month 15 primary endpoint

Item EX-99.1: Item EX-99.1

  • Q2 net loss $55.3M, or $0.28 per share, versus $49.2M and $0.34 in Q2 2025
  • Cash, equivalents and short-term investments $209.2M at June 30, with runway expected into 2028

Item EX-99.2: Item EX-99.2

  • ARCHER II adds Month 24 as a dual primary endpoint, creating a second opportunity to demonstrate vision-loss protection
  • Month 15 primary-endpoint assessment remains on schedule for Q4 2026, the next major valuation catalyst

Item 2.02: Results of Operations and Financial Condition

  • Annexon announced financial results for Q2 2026, ended June 30, 2026
  • Press release includes business updates and anticipated milestones relevant to clinical and corporate catalysts
Filed Aug 10, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Muneer Satter resigned immediately before successor appointment after more than 11 years, with no operational, policy, or strategy disagreement
  • Mark S. Blumenkranz appointed Class II director through 2028 annual meeting, adding ophthalmology expertise to the Board

Item EX-99.1: Item EX-99.1

  • Board adds Mark S. Blumenkranz, retinal specialist and biotechnology entrepreneur with over four decades of industry experience
  • Appointment strengthens strategic expertise for vonaprument’s geographic atrophy program and potential commercialization

Item 7.01: Regulation FD Disclosure

  • Board transition: Mr. Satter resigned and Dr. Blumenkranz was appointed
  • Dr. Blumenkranz’s appointment may add relevant expertise to Annexon’s strategic oversight

AI summaries of ANNX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ANNX

Don't miss the next ANNX filing

  • Alerts as it files. A push when ANNX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ANNX, by share count.
  • Ask anything. An AI agent that reads every ANNX filing and answers with sources.

ANNX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Carson William H.BuyNov 19, 2026$3.58
Love DouglasBuySep 24, 2026$3.83
Blumenkranz Mark S.AAug 10, 2026-
Yednock TedMJun 11, 2026-
JONES WILLIAM A JRAJun 11, 2026-
Choi JungAJun 11, 2026-
Waddill William D.AJun 11, 2026-
Carson William H.AJun 11, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$143.7M-$154.1M-$216.4M
Net Income--$138.2M-$206.7M
Balance Sheet
Total Assets$297.7M$350.1M$277.6M
Equity$250.6M$293.1M$211.6M
ROE--47.2%-97.7%
Per Share
EPS$-1.77$-1.01$-1.34
Cash Flow
Operating CF-$121.1M-$118.0M-$186.4M
CapEx$193K$15K$137K

Source: XBRL data in Annexon, Inc. (ANNX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ANNX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ANNX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$247.0M
Q2 202628$427.7M
Q1 202628$318.9M
Q4 202525$262.8M
Q3 202525$133.0M
Q2 202524$105.8M
Q1 202521$63.8M
Q4 202418$150.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 198 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ANNX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Sep 25, 2026--
4Aug 12, 2026--
10-QAug 12, 2026Analysis
8-KAug 12, 2026Analysis-
8-KAug 10, 2026Analysis-
SC 13GAug 7, 2026-
8-KAug 6, 2026Analysis-
8-KJul 30, 2026Analysis-
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
8-KJun 12, 2026Analysis-
4May 29, 2026-
4May 13, 2026-
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
4Apr 14, 2026--
8-KMar 30, 2026--

Related Health Care companies

All Health Care →

ANNX SEC filings: frequently asked questions

Are ANNX insiders buying or selling?

In the last 90 days, Annexon, Inc. (ANNX) officers, directors and 10% owners reported 2 open-market purchases worth $221,549 by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ANNX stock?

As of September 30, 2026, the largest Annexon, Inc. (ANNX) holders among the 13F filers tracked by SignalX were BlackRock ($60.3 million), State Street Corp ($40.2 million), Vanguard Capital Management LLC ($33.3 million), Ameriprise Financial ($25.4 million), Goldman Sachs Group ($16.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did ANNX report in its latest 8-K?

Annexon, Inc. (ANNX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter 2026 financial results announced for period ended September 30, 2026.

What are the latest ANNX SEC filings?

Annexon, Inc. (ANNX) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 20, 2026.

What is ANNX's SEC CIK number?

Annexon, Inc. (ANNX)'s SEC Central Index Key (CIK) is 1528115. EDGAR lists every ANNX filing under that number.

Ask anything about ANNX

The research agent reads ANNX's filings, financials, insider trades and 13F holders, then answers with sources.